Index | RUT |
P/E | - |
EPS (ttm) | -3.71 |
Insider Own | 72.95% |
Shs Outstand | 44.02M |
Perf Week | 41.19% |
Market Cap | 1.25B |
Forward P/E | - |
EPS next Y | -4.22 |
Insider Trans | 25.85% |
Shs Float | 11.48M |
Perf Month | 55.03% |
Enterprise Value | 948.75M |
PEG | - |
EPS next Q | -1.06 |
Inst Own | 28.04% |
| |
Perf Quarter | 83.13% |
Income | -161.15M |
P/S | - |
EPS this Y | 76.92% |
Inst Trans | 62.38% |
| |
Perf Half Y | - |
Sales | 0.00M |
P/B | 2.82 |
EPS next Y | 1.39% |
ROA | - |
| |
Perf YTD | 67.44% |
Book/sh | 10.41 |
P/C | 4.09 |
EPS next 5Y | 36.25% |
ROE | - |
52W High | 25.79 14.04% |
Perf Year | - |
Cash/sh | 7.19 |
P/FCF | - |
EPS past 3/5Y | -71.59% - |
ROIC | -34.78% |
52W Low | 12.24 140.28% |
Perf 3Y | - |
Dividend Est. | - |
EV/EBITDA | - |
Sales past 3/5Y | - - |
Gross Margin | - |
Volatility | 11.63% 8.96% |
Perf 5Y | - |
Dividend TTM | - |
EV/Sales | - |
EPS Y/Y TTM | - |
Oper. Margin | - |
ATR (14) | 1.86 |
Perf 10Y | - |
Dividend Ex-Date | - |
Quick Ratio | 20.01 |
Sales Y/Y TTM | - |
Profit Margin | - |
RSI (14) | 86.22 |
| |
Dividend Gr. 3/5Y | - - |
Current Ratio | 20.01 |
EPS Q/Q | -306.87% |
SMA20 | 47.62% |
Beta | - |
| |
Payout | - |
Debt/Eq | 0.01 |
Sales Q/Q | - |
SMA50 | 57.67% |
Rel Volume | 2.63 |
Prev Close | 24.24 |
Employees | 133 |
LT Debt/Eq | 0.01 |
| |
SMA200 | 65.82% |
Avg Volume | 210.28K |
Price | 29.41 |
IPO | Oct 27, 2025 |
Option/Short | No / Yes |
| |
Trades | |
Volume | 534,813 |
Change | 21.33% |
|
 |
|
|
|
| |
| Date |
Action |
Analyst |
Rating Change |
Price Target Change |
| Apr-08-26 | Initiated |
Needham |
Buy |
$37 |
| Apr-07-26 | Initiated |
TD Cowen |
Buy |
|
| Mar-19-26 | Initiated |
Canaccord Genuity |
Buy |
$35 |
| Nov-21-25 | Initiated |
Stifel |
Buy |
$28 |
| Nov-21-25 | Initiated |
Morgan Stanley |
Overweight |
$34 |
| Nov-21-25 | Initiated |
Leerink Partners |
Outperform |
$30 |
| Nov-21-25 | Initiated |
Jefferies |
Buy |
$32 |
|
|
|
Mar-26-26 07:00AM
|
|
|
Mar-02-26 07:00AM
|
|
|
Jan-09-26 07:00AM
|
|
|
Jan-05-26 07:00AM
|
|
|
Dec-16-25 07:00AM
|
|
| 07:00AM |
Loading… |
|
Dec-04-25 07:00AM
|
|
|
Nov-07-25 07:26PM
|
|
|
Oct-29-25 09:06AM
|
|
|
Oct-26-25 05:30PM
|
|
|
|
|
|
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA. | |
|
|
|
| |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Malenka Robert C. | Director | Feb 23 '26 | Sale | 18.42 | 11,264 | 207,464 | 325,795 | Feb 24 06:57 PM | | Malenka Robert C. | Director | Feb 20 '26 | Sale | 18.03 | 2,195 | 39,576 | 337,059 | Feb 24 06:57 PM | | Malenka Robert C. | Director | Feb 24 '26 | Sale | 18.15 | 736 | 13,358 | 325,059 | Feb 24 06:57 PM | | ROBERT MALENKA | Director | Feb 24 '26 | Proposed Sale | 18.14 | 736 | 13,355 | | Feb 24 04:36 PM | | ROBERT MALENKA | Director | Feb 23 '26 | Proposed Sale | 18.42 | 11,264 | 207,491 | | Feb 23 04:33 PM | | Pavlov George | Director | Feb 18 '26 | Buy | 17.48 | 10,658 | 186,302 | 10,658 | Feb 20 06:25 PM | | Pavlov George | Director | Feb 20 '26 | Buy | 17.86 | 9,920 | 177,171 | 25,000 | Feb 20 06:25 PM | | Pavlov George | Director | Feb 19 '26 | Buy | 17.57 | 4,422 | 77,695 | 15,080 | Feb 20 06:25 PM | | ROBERT MALENKA | Director | Feb 20 '26 | Proposed Sale | 18.03 | 2,195 | 39,577 | | Feb 20 04:16 PM | | Malenka Robert C. | Director | Feb 13 '26 | Sale | 18.21 | 12,116 | 220,632 | 339,254 | Feb 18 07:33 PM | | ROBERT MALENKA | Director | Feb 13 '26 | Proposed Sale | 18.21 | 12,116 | 220,686 | | Feb 13 04:08 PM | | Garnett Timothy John | Director | Feb 10 '26 | Buy | 17.89 | 14,124 | 252,678 | 14,124 | Feb 12 05:45 PM | | Malenka Robert C. | Director | Feb 10 '26 | Sale | 18.12 | 6,622 | 119,991 | 351,611 | Feb 12 05:45 PM | | Malenka Robert C. | Director | Feb 11 '26 | Sale | 18.00 | 241 | 4,338 | 351,370 | Feb 12 05:45 PM | | ROBERT MALENKA | Director | Feb 11 '26 | Proposed Sale | 18.00 | 241 | 4,338 | | Feb 11 04:13 PM | | ROBERT MALENKA | Director | Feb 10 '26 | Proposed Sale | 18.12 | 6,622 | 119,963 | | Feb 10 04:22 PM | | Malenka Robert C. | Director | Feb 02 '26 | Sale | 18.02 | 7,039 | 126,843 | 358,234 | Feb 04 09:15 PM | | Malenka Robert C. | Director | Feb 03 '26 | Sale | 18.00 | 1 | 18 | 358,233 | Feb 04 09:15 PM | | ROBERT MALENKA | Director | Feb 03 '26 | Proposed Sale | 18.00 | 1 | 18 | | Feb 03 04:15 PM | | ROBERT MALENKA | Director | Feb 02 '26 | Proposed Sale | 18.02 | 7,039 | 126,835 | | Feb 02 04:37 PM | | Malenka Robert C. | Director | Jan 29 '26 | Sale | 18.55 | 21,262 | 394,410 | 371,885 | Jan 30 08:50 PM | | Malenka Robert C. | Director | Jan 28 '26 | Sale | 18.65 | 6,524 | 121,704 | 393,147 | Jan 30 08:50 PM | | Malenka Robert C. | Director | Jan 30 '26 | Sale | 18.11 | 6,612 | 119,743 | 365,273 | Jan 30 08:50 PM | | ROBERT MALENKA | Director | Jan 30 '26 | Proposed Sale | 18.11 | 6,612 | 119,737 | | Jan 30 04:17 PM | | ROBERT MALENKA | Director | Jan 29 '26 | Proposed Sale | 18.55 | 21,262 | 394,470 | | Jan 29 04:06 PM | | ROBERT MALENKA | Director | Jan 28 '26 | Proposed Sale | 18.65 | 6,524 | 121,690 | | Jan 28 04:20 PM | | Novo Holdings A/S | 10% Owner | Oct 28 '25 | Buy | 17.00 | 952,941 | 16,199,997 | 3,686,622 | Oct 30 04:31 PM | | Catalyst4, Inc. | 10% Owner | Oct 28 '25 | Buy | 17.00 | 5,441,176 | 92,499,992 | 19,697,464 | Oct 29 04:16 PM |
|
|
